Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Tim K who wrote (2504)	9/3/1998 9:12:00 AM
From: EZLibra	Read Replies (2) \| Respond to of 3702

Hi Tim. It is a fact that TNT does very well therapeutically in prostate cancer. There was a Phase I trial begun under a California IND years ago. Four terminal cases were successfully imaged. There were two responses and one complete remission on a diagnostic dose, if memory serves. The subjects were all members of a national prostate organization. The problem was the trial was being paid for by the patients themselves and FDA doesn't allow that. According to last night's TV the same mentality held up Herceptin approval for 4-5 years. IMO the process has been re-proven on prostate cancer in China and is now being implemented with the new label, NIH pump and rad dosing in Mexico. Consequently in the not too distant future I feel a very efficacious TNT will be trialed on prostate cancer here in the good 'ol stuck-in-a-rut U.S.A. BTW, some yahoo newbie claimed the Mexico trials had been halted for some unknown reason. That's total horse-hockey. Everyone should remember there is an active short position and they will say anything and do anything to discourage the long investor. They have proven this over and over. Labor Day and the Rubinstein rollout will arrive shortly, let's see how the story unfolds. Onward and upward!